MXCT MaxCyte, Inc.
USHealthcareAs of 2026-07-10 16:00
Why MXCT matters now
MaxCyte, Inc. (MXCT) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.33 with +3.91% on the session and $142.5M in market capitalization; recent performance reads 1-month +16.35% and YTD -21.94%.
The latest financial table shown here is Q1 2026, with revenue of $9.7M, net income of $-4.8M, and EPS of $-0.04. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -22.8%.
The latest indexable market news headline is "VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Ahuja Parmeet filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.77
P/S
4.01
EV/EBITDA
-3.83
DCF Value
$-2.77
FCF Yield
-22.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.7%
Operating Margin
-119.7%
Net Margin
-121.2%
ROE
-22.0%
ROA
-20.1%
ROIC
-20.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $9.7M | $-4.8M | $-0.04 |
| Q4 2025 | $7.3M | $-9.6M | $-0.09 |
| FY 2025 | $33.0M | $-44.6M | $-0.42 |
| Q3 2025 | $6.8M | $-12.4M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.67
MaxCyte, Inc. is a global life sciences enterprise focused on the innovation, advancement, and commercialization of next-generation cell therapies. The company offers a suite of advanced electroporation systems, including the ExPERT ATx, a static device for small to medium-scale cell transfection; the ExPERT STx, which uses flow electroporation to support protein production, drug development, and the expression of therapeutic targets for cell-based assays; the ExPERT GTx, another flow electroporation solution designed for large-scale transfection in therapeutic applications; and the ExPERT VLx, catering to very high-volume cell engineering needs. Additionally, MaxCyte provides disposable processing assemblies (PAs) crucial for cell processing and electroporation, alongside essential accessories such as electroporation buffer solutions and specialized software protocols. The company, established in 1998, operates from its headquarters in Rockville, Maryland.